We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Pnl1.5
Pinealon Research
Mostly mechanism / observationalLimited safety
9 peer-reviewed studies
What the evidence says
Mostly mechanism / observational
Most Pinealon studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from mixed-quality studies published 2012–2026.
Based on 9 studies
Confidence
Low
By outcome
Neuroprotection & brain aging
Mostly mechanism / observational4 studies
Cognitive function
Mostly mechanism / observational3 studies
Longevity & aging
Mostly mechanism / observational3 studies
Active research area
3 studies in the last 5 years
201220192026
1Systematic Review2026
This review integrates current mechanistic insights with orthopaedic relevance, emphasizing safety, efficacy, and future directions for responsible integration into musculoskeletal care.
Rahman OF, Lee SJ, Seeds WA. · Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews (2026)
Recovery-enhancing agents such as epithalon, delta sleep-inducing peptide, and pinealon target circadian and mitochondrial regulators, and neuroactive peptides like selank, semax, and dihexa enhance brain-derived neurotrophic factor and HGF/c-Met pathways critical to neuroplasticity.
Although preclinical studies are promising, there is a current lack of clinical trials.
This review integrates current mechanistic insights with orthopaedic relevance, emphasizing safety, efficacy, and future directions for responsible integration into musculoskeletal care.
Leu-Ile, Glu-Trp, Lys-Glu, Gly-Pro, Glu-Asp-Arg, Lys-Glu-Asp, Met-Glu-His-Phe-Pro-Gly-Pro short peptides are described as multitarget agents with a wide range of activity.
Alzheimer's disease (AD) is the most common neurodegenerative disorder, characterized by progressive cognitive decline.
This review discusses current therapeutic strategies for the treatment of Alzheimer's disease, their limitations, and potential prospects.
The feasibility of comprehensive approach for AD therapy is considered in contrast to the classical method in the development of therapeutic strategy.
3Review2020
The EDR peptide (Glu-Asp-Arg) has been previously established to possess neuroprotective properties.
Khavinson V, Linkova N, Kozhevnikova E, Trofimova S. · Molecules (2020)
Review from the originating group laying out the proposed mechanism of the EDR (Glu-Asp-Arg) peptide in neuroprotection
Proposes EDR enters cells and binds histones/RNA, altering the MAPK/ERK pathway and synthesis of proapoptotic (caspase-3, p53) and antioxidant (SOD2, GPX1) proteins
States EDR interferes with dendritic-spine elimination in Alzheimer's/Huntington's neuronal cultures and 'improves memory issues in elderly patients'
Animal study: aged rats under acute hypoxic hypoxia, examining caspase-3 activity in brain and IL-6 / TNF in serum
Pinealon (Glu-Asp-Arg) was associated with increased neurogenesis and a decrease in neuroinflammatory reactions toward reference levels under brain hypoxia
Compared against Cortexin, which reduced programmed cell death but kept IL-6 elevated
7Open-Label2015
The preparations of "Pinealon" and "Vesugen" have had the significant anabolic effect.
Meshchaninov VN, Tkachenko EL, Zharkov SV, Gavrilov IV, Katyreva IuE. · Adv Gerontol (2015)
Small human study (32 people, aged 41-83) with polymorbidity and organic brain syndrome in remission, using Pinealon and Vesugen
Reported anabolic effects and slowed biological-age indicators, with Vesugen showing a more visible effect than Pinealon
Crucially also found prooxidant activity by chemiluminescence and a significant decrease in CD34+ haematopoietic markers — flagged as needing future study
8Open-Label2016
The most pronounced positive impact on indicators of biological age were detected during the combined use of these two Oligopeptide complexes.
Human study of 110 people across age groups comparing several geroprotective methods, including the oligopeptides Vezugen and Pinealon (Glu-Asp-Arg)
The combined use of the two peptides gave the most pronounced positive impact on biological-age indicators
The oligopeptide preparations were rated among the safest of the methods compared on biochemical, immunological, and clinical parameters
9Open-Label2012
Workers of locomotive brigades used preparation during two weeks (1 capsule containing 100 mkg of Pinealon 2 times a day). Pinealon application has improved parameters of biological age and indicators determining the effectiveness of adaptive reactions.
Nazimko VA, Morgul' EV, Petrova OA, Sheĭkhova RG, Kozina LS, Savenko MA, Lysenko DS. · Adv Gerontol (2012)
Small, open, uncontrolled human report in locomotive-brigade workers exposed to occupational stress
Used oral Pinealon capsules of 100 mcg twice daily for two weeks — the source of the only published human dosing reference
Claimed improved biological-age parameters and adaptive-reaction indicators